ARTBIO
Emanuele Ostuni is the CEO of ARTBIO and serves as a Scientific Advisory Board Member at Elicio Therapeutics. With a Ph.D in Chemistry from Harvard University, their extensive professional experience includes roles such as Head of Europe, Cell and Gene Therapy at Novartis Oncology, Vice President of Business Development at Nano Terra, and Co-Founder at Enumeral Biomedical Holdings, Inc. They have also held positions at Sandoz, McKinsey & Company, Surface Logix, and Harvard University.
This person is not in any offices
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.